Showing results (71-80 of 139) with videos related to
Sort By:
Pageof 14
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 20, 2019
Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)Jean Marc Phelip, David Tougeron, David Léonard, et al.Cancer Research Communications|January 14, 2025
Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT TrialsAngélique Vienot, Dewi Vernerey, Adeline Bouard, et al.Bulletin Du Cancer|November 24, 2004
[Clinical practice guideline: 2003 update of Standards, Options et Recommendations for first line palliative chemotherapy in patients with metastatic colorectal cancer (summary report)]Thierry Conroy, Guillaume Gory-Delabaere, Antoine Adenis, et al.Molecular Oncology|May 2, 2021
Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatmentBrice Pastor, Thierry André, Julie Henriques, et al.Cancer Imaging : the Official Publication of the International Cancer Imaging Society|December 11, 2019
RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter studyOlivier Lucidarme, Mathilde Wagner, Paul Gillard, et al.Journal of Neuro-Oncology|January 3, 2025
The METACER national cohort study of brain metastases in gastrointestinal cancers prospectively establishes prognostic factorsViolaine Randrian, Fabienne Portales, Olivier Bouché, et al.European Journal of Cancer (Oxford, England : 1990)|April 30, 2022
Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II studyBenoit Rousseau, Arezki K Boukerma, Julie Henriques, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2011
Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapyAziz Zaanan, Jean-François Fléjou, Jean-François Emile, et al.Cancers|March 24, 2019
Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer PatientsLuc Cabel, Charles Decraene, Ivan Bieche, et al.European Journal of Cancer (Oxford, England : 1990)|October 5, 2023
Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancerCosimo Rasola, Pierre Laurent-Puig, Thierry André, et al.Pageof 14